All In Biotech

Drug Trial Radar · NCT03711604

Compassionate Use Study of Tenalisib (RP6530)

An Open Label, Compassionate Use Study of Tenalisib (RP6530) in Patients Currently Receiving Treatment on Tenalisib Trials in Hematological Malignancies

Last checked: Nov 19, 2026Latest source record: May 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

17

Actual

Start

Nov 28, 2018

Primary completion

Mar 25, 2023

Study completion Mar 25, 2023

Sponsor

Lead sponsor
Rhizen Pharmaceuticals SAIndustry
Sponsor type
Industry
First posted
Oct 18, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Tenalisib has been evaluated as an investigational new drug in number of early clinical studies in patients with relapsed/refractory hematological malignancies and demonstrated acceptable safety and promising efficacy in these patients. Since these advanced relapsed/refractory patients have limited therapeutic options, it is reasonable to continue Tenalisib in responding patients post completion of their participation in previous clinical studies.

Conditions

  • Hematological Malignancies

Interventions

  • TenalisibDrug

    BID Orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-related Adverse EventsTime frame: 2 years
  2. Time to Disease ProgressionTime frame: 2 years

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • University of California, Hellen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • Division of Hematology, University of Colorado,

    Denver, Colorado

  • Cleveland Clinic Taussig Cancer Institute

    Cleveland, Ohio

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Ltd. M.Zodelava Hematology Centre

    Tbilisi, Georgia

  • Medivest - Institute of Hematology and Transfusiology

    Tbilisi, Georgia

  • Silesian Healthy Blood Clinic Grosicki, Grosicka Sp.J.

    Chorzów, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.